Streetbeat News

Stock Prices

CLOV

NVNO

SRPT

Market-Moving News for June 21st: Sarepta Therapeutics (SRPT) shares surged 45% after FDA approval for ELEVIDYS expansion and multiple price target raises. Clover Health (CLOV) shares rose 13% following a significant share purchase by a director. EnVVeno Medical (NVNO) shares increased 16% after positive interim data from the SAVVE U.E. trial.

Portfolio Pulse from ryanfaloona@benzinga.com

June 21, 2024 | 12:42 pm

NVNO

EnVVeno Medical shares are trading higher following the release of interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve. The data will be presented at the Society for Vascular Surgery 2024 Annual Meeting.

Portfolio Pulse from Bill Haddad

June 21, 2024 | 12:40 pm

BTCUSD

DWAC

ETHUSD

NVDA

TSLA

The article covers a range of topics including cryptocurrency market trends, US political updates, and significant movements in the tech and EV sectors. Key highlights include Standard Chartered's launch of a Bitcoin and Ethereum trading desk, Nvidia's acquisition of Shoreline.Io, and Tesla's new Supercharger setup. Additionally, Donald Trump shares his economic growth strategy and faces various political challenges.

Portfolio Pulse from Akanksha Bakshi

June 21, 2024 | 12:40 pm

NVNO

EnVVeno Medical reported positive interim data from its SAVVE U.E. pivotal trial for the VenoValve, showing significant healing in venous ulcer patients. The company plans to seek FDA approval in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 12:39 pm

ADBE

AMAT

HOV

NVDA

Insiders at Nvidia, Applied Materials, Hovnanian Enterprises, and Adobe have recently sold significant shares. Insider sales can indicate concerns about company prospects or overvaluation. Notable sales include Nvidia's CEO selling 240,000 shares and Applied Materials' CEO selling 400,000 shares.

Portfolio Pulse from Avi Kapoor

June 21, 2024 | 12:30 pm

CLOV

DMTK

SPEC

SRPT

TPHS

Sarepta Therapeutics shares surged 35.2% in pre-market trading following expanded FDA approval of ELEVIDYS for Duchenne Muscular Dystrophy patients aged 4 and above. Other notable pre-market movers include Spectaire Holdings, DermTech, and Trinity Place Holdings among others.

Portfolio Pulse from Avi Kapoor

June 21, 2024 | 12:22 pm

ENOV

PEN

RGEN

The article highlights three oversold health care stocks with RSI values near or below 30, indicating potential buying opportunities. The stocks mentioned are Repligen Corp (RGEN), Enovis Corp (ENOV), and Penumbra Inc (PEN).

Portfolio Pulse from Avi Kapoor

June 21, 2024 | 12:22 pm

AEI

CLOV

GLYC

VXRT

Insiders are aggressively buying shares of four penny stocks: Vaxart, Clover Health Investments, Alset, and GlycoMimetics. These transactions indicate confidence in the companies' prospects. Notable insider purchases include Vaxart's director buying 20,000 shares, Clover Health's director acquiring 877,567 shares, Alset's CEO buying 50,000 shares, and GlycoMimetics' CFO purchasing 17,500 shares.

Portfolio Pulse from Avi Kapoor

June 21, 2024 | 12:22 pm

NVDA

TSLA

Tesla Inc. (NASDAQ:TSLA) plans to expand its Giga Texas facility to include a new data center with over 500MW capacity in the next 18 months. This center will house Tesla's AI hardware and Nvidia's GPUs. Tesla will spend $3-4 billion on Nvidia hardware and the rest of its $10 billion AI budget internally.

Portfolio Pulse from Anan Ashraf

June 21, 2024 | 12:20 pm

NKLA

Nikola Corporation (NASDAQ:NKLA) shares are gaining in the premarket session after a significant 31.5% dip the previous day. The company announced a 1-for-30 reverse stock split effective June 24, aiming to increase its stock price and prevent delisting. However, challenges persist, including a multi-billion dollar lawsuit from founder Trevor Milton and removal from the Russell 3000 Index. Nikola's Q1 results showed a decline in sales and production compared to the previous year.

Portfolio Pulse from Nabaparna Bhattacharya

June 21, 2024 | 12:19 pm